Overview

A Bioequivalence Study to Compare the Pharmacokinetics of Two Betrixaban Formulations

Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
This is a single center open label randomized 4-period 2-sequence replicated crossover design study. A total of 52 healthy subjects will be randomized.
Phase:
Phase 1
Details
Lead Sponsor:
Portola Pharmaceuticals
Treatments:
Betrixaban